The role of α-synuclein in neurodegenerative diseases

Pharmacology and Therapeutics

Volumn 105, Issue 3, 2005, Pages 311-331

  Bennett, M Catherine ^a  

^a Blanchette Rockefeller Neurosci I   (United States)

Author keywords

Dopamine transporter; Endocytosis; Fibrillation; Iron; LBD; Lewy bodies; Muscarinic receptors; Nitration; Oxidative stress; Parkinson's disease; Protein aggregation; Protofibrils; Serine phosphorylation; Synucleopathy; Tissue transglutaminase; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROPROPIONIC ACID; ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; CARBON MONOXIDE; COPPER ION; CYANIDE; FERROUS ION; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HYDROGEN PEROXIDE; MANGANESE; METHYL 4 PHENYLPYRIDINIUM; MITOCHONDRIAL ENZYME; MITOCHONDRIAL ENZYME INHIBITOR; NEUROTOXIN; OLIGOMYCIN; PARKIN; PROTEASOME INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; SODIUM AZIDE; TOXIN; TRANSITION ELEMENT; TYROSINE 3 MONOOXYGENASE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALPHA HELIX; ALZHEIMER DISEASE; BRAIN REGION; DEGENERATIVE DISEASE; DEMENTIA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE MUTATION; GENE TRANSLOCATION; HUMAN; IN VITRO STUDY; LEWY BODY; MOTOR DYSFUNCTION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; UPREGULATION;

EID: 14344263884     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2004.10.010     Document Type: Review

References (216)

1. N. Abbas, C.B. Lucking, S. Ricard, A. Durr, V. Bonifati, and M.G. De A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease Hum Mol Genet 8 1999 567 574
2. A. Abeliovich, Y. Schmitz, I. Farinas, D. Choi-Lundberg, W.H. Ho, and P.E. Castillo Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system Neuron 25 2000 239 252
3. V. Alvarez, L.M. Guisasola, V.G. Moreira, C.H. Lahoz, and E. Coto Early-onset Parkinson's disease associated with a new parkin mutation in a Spanish family Neurosci Lett 313 2001 108 110
4. K. Ancolio, C.C. ves da, K. Ueda, and F. Checler Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells Neurosci Lett 285 2000 79 82
5. G. Andringa, F. Du, T.N. Chase, and M.C. Bennett Mapping of rat brain using the Synuclein-1 monoclonal antibody reveals somatodendritic expression of alpha-synuclein in populations of neurons homologous to those vulnerable to Lewy body formation in human synucleopathies J Neuropathol Exp Neurol 62 2003 1060 1075
6. G. Andringa, J.G.J.M. Bol, X. Wang, M.C. Bennett, T.N. Chase, and B. Drukarch Changed distribution pattern of the constitutive rather than the inducible HSP 70 chaperone in neuromelanin-containing neurons of the Parkinsonian midbrain Brain Pathol 2004 (in press)
7. G. Andringa, K.Y. Lam, M. Chegary, X. Wang, T.N. Chase, and M.C. Bennett Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease FASEB J 18 2004 932 934
8. H. Arai, V.M. Lee, W.D. Hill, B.D. Greenberg, and J.Q. Trojanowski Lewy bodies contain beta-amyloid precursor proteins of Alzheimer's disease Brain Res 585 1992 386 390
9. S. Arawaka, Y. Saito, S. Murayama, and H. Mori Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein Neurology 51 1998 887 889
10. K. Arima, K. Ueda, N. Sunohara, K. Arakawa, S. Hirai, and M. Nakamura NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy Acta Neuropathol (Berl) 96 1998 439 444
11. K. Arima, K. Ueda, N. Sunohara, S. Hirai, Y. Izumiyama, and H. Tonozuka-Uehara Immunoelectron-microscopic demonstration of NACP/alpha- synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies Brain Res 808 1998 93 100
12. P.K. Auluck, H.Y. Chan, J.Q. Trojanowski, V.M. Lee, and N.M. Bonini Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease Science 295 2002 865 868
13. M. Baba, S. Nakajo, P.H. Tu, T. Tomita, K. Nakaya, and V.M. Lee Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies Am J Pathol 152 1998 879 884
14. T.A. Bayer, P. Jakala, T. Hartmann, L. Havas, C. McLean, and J.G. Culvenor Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores Neurosci Lett 266 1999 213 216
15. N.F. Bence, R.M. Sampat, and R.R. Kopito Impairment of the ubiquitin-proteasome system by protein aggregation Science 292 2001 1552 1555
16. M.C. Bennett, J.F. Bishop, Y. Leng, P.B. Chock, T.N. Chase, and M.M. Mouradian Degradation of alpha-synuclein by proteasome J Biol Chem 274 1999 33855 33858
17. R. Betarbet, T.B. Sherer, G. MacKenzie, M. Garcia-Osuna, A.V. Panov, and J.T. Greenamyre Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat Neurosci 3 2000 1301 1306
18. M.L. Bleecker Parkinsonism: a clinical marker of exposure to neurotoxins Neurotoxicol Teratol 10 1988 475 478
19. A.M. Bodles, D.J. Guthrie, P. Harriott, P. Campbell, and G.B. Irvine Toxicity of non-Abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils Eur J Biochem 267 2000 2186 2194
20. V. Bonifati, M.C. Dekker, N. Vanacore, G. Fabbrini, F. Squitieri, and R. Marconi Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7 Neurol Sci 23 Suppl. 2 2002 S59 S60
21. H. Braak, D. Sandmann-Keil, W. Gai, and E. Braak Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry Neurosci Lett 265 1999 67 69
22. R. Bussell Jr., and D. Eliezer A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins J Mol Biol 329 2003 763 778
23. R. Bussell Jr., and D. Eliezer Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein Biochemistry 43 2004 4810 4818
24. B. Caughey, and P.T. Lansbury Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders Annu Rev Neurosci 26 2003 267 298
25. P. Chan, X. Jiang, L.S. Forno, D.A. Di Monte, C.M. Tanner, and J.W. Langston Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease Neurology 50 1998 1136 1137
26. P. Chan, C.M. Tanner, X. Jiang, and J.W. Langston Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease Neurology 50 1998 513 514
27. P. Choi, N. Golts, H. Snyder, M. Chong, L. Petrucelli, and J. Hardy Co-association of parkin and alpha-synuclein Neuroreport 12 2001 2839 2843
28. A. Ciechanover, A. Laszlo, B. Bercovich, I. Stancovski, I. Alkalay, and Y. Ben-Neriah The ubiquitin-mediated proteolytic system: involvement of molecular chaperones, degradation of oncoproteins, and activation of transcriptional regulators Cold Spring Harb Symp Quant Biol 60 1995 491 501
29. B.A. Citron, Z. Suo, K. SantaCruz, P.J. Davies, F. Qin, and B.W. Festoff Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration Neurochem Int 40 2002 69 78
30. N.B. Cole, D.D. Murphy, T. Grider, S. Rueter, D. Brasaemle, and R.L. Nussbaum Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein J Biol Chem 277 2002 6344 6352
31. 2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization Curr Biol 7 1997 191 201
32. K.A. Conway, J.D. Harper, and P.T. Lansbury Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease Nat Med 4 1998 1318 1320
33. K.A. Conway, J.D. Harper, and P.T. Lansbury Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid Biochemistry 39 2000 2552 2563
34. K.A. Conway, S.J. Lee, J.C. Rochet, T.T. Ding, J.D. Harper, and R.E. Williamson Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants Ann N Y Acad Sci 920 2000 42 45
35. K.A. Conway, S.J. Lee, J.C. Rochet, T.T. Ding, R.E. Williamson, and P.T. Lansbury Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy Proc Natl Acad Sci U S A 97 2000 571 576
36. K.A. Conway, J.C. Rochet, R.M. Bieganski, and P.T. Lansbury Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct Science 294 2001 1346 1349
37. R.A. Crowther, S.E. Daniel, and M. Goedert Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain Neurosci Lett 292 2000 128 130
38. J.G. Culvenor, C.A. McLean, S. Cutt, B.C. Campbell, F. Maher, and P. Jakala Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid Am J Pathol 155 1999 1173 1181
39. C.A. da Costa, K. Ancolio, and F. Checler Wild-type but not Parkinson's disease-related ala-53-thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli J Biol Chem 275 2000 24065 24069
40. E. Dalfo, T. Gomez-Isla, J.L. Rosa, B.M. Nieto, T.M. Cuadrado, and M. Barrachina Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice J Neuropathol Exp Neurol 63 2004 302 313
41. W. Dauer, N. Kholodilov, M. Vila, A.C. Trillat, R. Goodchild, and K.E. Larsen Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP Proc Natl Acad Sci U S A 99 2002 14524 14529
42. W.S. Davidson, A. Jonas, D.F. Clayton, and J.M. George Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes J Biol Chem 273 1998 9443 9449
43. T.T. Ding, S.J. Lee, J.C. Rochet, and P.T. Lansbury Jr. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes Biochemistry 41 2002 10209 10217
44. M.J. Doherty, T.D. Bird, and J.B. Leverenz Alpha-synuclein in motor neuron disease: an immunohistologic study Acta Neuropathol (Berl) 107 2004 169 175
45. Z. Dong, B. Ferger, J. Feldon, and H. Bueler Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP J Neurobiol 53 2002 1 10
46. J.E. Duda, B.I. Giasson, Q. Chen, T.L. Gur, H.I. Hurtig, and M.B. Stern Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies Am J Pathol 157 2000 1439 1445
47. O.M. El-Agnaf, R. Jakes, M.D. Curran, D. Middleton, and R. Ingenito Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments FEBS Lett 440 1998 71 75
48. O.M. El-Agnaf, R. Jakes, M.D. Curran, and A. Wallace Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease FEBS Lett 440 1998 67 70
49. M.B. Feany, and W.W. Bender A Drosophila model of Parkinson's disease Nature 404 2000 394 398
50. L.S. Forno Neuropathology of Parkinson's disease J Neuropathol Exp Neurol 55 1996 259 272
51. H. Fujiwara, M. Hasegawa, N. Dohmae, A. Kawashima, E. Masliah, and M.S. Goldberg Alpha-synuclein is phosphorylated in synucleinopathy lesions Nat Cell Biol 4 2002 160 164
52. W.P. Gai, J.H. Power, P.C. Blumbergs, J.G. Culvenor, and P.H. Jensen Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components J Neurochem 73 1999 2093 2100
53. W.P. Gai, H.X. Yuan, X.Q. Li, J.T. Power, P.C. Blumbergs, and P.H. Jensen In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies Exp Neurol 166 2000 324 333
54. P.G. Galloway, and G. Perry Tropomyosin distinguishes Lewy bodies of Parkinson disease from other neurofibrillary pathology Brain Res 541 1991 347 349
55. P.G. Galloway, I. Grundke-Iqbal, K. Iqbal, and G. Perry Lewy bodies contain epitopes both shared and distinct from Alzheimer neurofibrillary tangles J Neuropathol Exp Neurol 47 1988 654 663
56. J.E. Galvin, K. Uryu, V.M. Lee, and J.Q. Trojanowski Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein Proc Natl Acad Sci U S A 96 1999 13450 13455
57. T. Gasser Autosomal-dominantly inherited forms of Parkinson's disease J Neural Transm Suppl 2000 31 40
58. B.I. Giasson, K. Uryu, J.Q. Trojanowski, and V.M. Lee Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro J Biol Chem 274 1999 7619 7622
59. B.I. Giasson, J.E. Duda, I.V. Murray, Q. Chen, J.M. Souza, and H.I. Hurtig Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions Science 290 2000 985 989
60. B.I. Giasson, J.E. Duda, M.S. Forman, V.M. Lee, and J.Q. Trojanowski Prominent perikaryal expression of alpha- and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons Exp Neurol 172 2001 354 362
61. S. Gispert, T.D. Del, L. Garrett, A. Chen, D.J. Bernard, and J. Hamm-Clement Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation Mol Cell Neurosci 24 2003 419 429
62. J.E. Goldman, S.H. Yen, F.C. Chiu, and N.S. Peress Lewy bodies of Parkinson's disease contain neurofilament antigens Science 221 1983 1082 1084
63. T. Gomez-Isla, M.C. Irizarry, A. Mariash, B. Cheung, O. Soto, and S. Schrump Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice Neurobiol Aging 24 2003 245 258
64. C. Gomez-Santos, I. Ferrer, J. Reiriz, F. Vinals, M. Barrachina, and S. Ambrosio MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells Brain Res 935 2002 32 39
65. H. Han, P.H. Weinreb, and P.T. Lansbury Jr. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem Biol 2 1995 163 169
66. A. Hartmann, J.D. Troadec, S. Hunot, K. Kikly, B.A. Faucheux, and A. Mouatt-Prigent Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis J Neurosci 21 2001 2247 2255
67. T. Hasegawa, M. Matsuzaki, A. Takeda, A. Kikuchi, H. Akita, and G. Perry Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells Brain Res 1013 2004 51 59
68. M. Hashimoto, L.J. Hsu, A. Sisk, Y. Xia, A. Takeda, and M. Sundsmo Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease Brain Res 799 1998 301 306
69. M. Hashimoto, L.J. Hsu, Y. Xia, A. Takeda, A. Sisk, and M. Sundsmo Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro Neuroreport 10 1999 717 721
70. M. Hashimoto, L.J. Hsu, E. Rockenstein, T. Takenouchi, M. Mallory, and E. Masliah Alpha-synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells J Biol Chem 277 2002 11465 11472
71. N. Hattori, T. Kitada, H. Matsumine, S. Asakawa, Y. Yamamura, and H. Yoshino Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals Ann Neurol 44 1998 935 941
72. R.E. Heikkila, A. Hess, and R.C. Duvoisin Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase. MPTP metabolism and neurotoxicity Life Sci 36 1985 231 236
73. L.J. Hsu, Y. Sagara, A. Arroyo, E. Rockenstein, A. Sisk, and M. Mallory Alpha-synuclein promotes mitochondrial deficit and oxidative stress Am J Pathol 157 2000 401 410
74. H.I. Hurtig, J.Q. Trojanowski, J. Galvin, D. Ewbank, M.L. Schmidt, and V.M. Lee Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease Neurology 54 2000 1916 1921
75. K. Ii, H. Ito, K. Tanaka, and A. Hirano Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly J Neuropathol Exp Neurol 56 1997 125 131
76. M.C. Irizarry, W. Growdon, T. Gomez-Isla, K. Newell, J.M. George, and D.F. Clayton Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity J Neuropathol Exp Neurol 57 1998 334 337
77. A. Iwai, E. Masliah, M. Yoshimoto, N. Ge, L. Flanagan, and H.A. de Silva The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system Neuron 14 1995 467 475
78. T. Iwatsubo, I. Nakano, K. Fukunaga, and E. Miyamoto Ca2+/calmodulin- dependent protein kinase II immunoreactivity in Lewy bodies Acta Neuropathol (Berl) 82 1991 159 163
79. R.S. Jaeckle, and H.A. Nasrallah Major depression and carbon monoxide-induced parkinsonism: diagnosis, computerized axial tomography, and response to l-dopa J Nerv Ment Dis 173 1985 503 508
80. R. Jakes, M.G. Spillantini, and M. Goedert Identification of two distinct synucleins from human brain FEBS Lett 345 1994 27 32
81. C.C. Jao, A. Der-Sarkissian, J. Chen, and R. Langen Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling PNAS USA 101 2004 8331 8336
82. F. Javoy, C. Sotelo, A. Herbet, and Y. Agid Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system Brain Res 102 1976 201 215
83. 2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins Biochemistry 37 1998 4901 4909
84. P.H. Jensen, E.S. Sorensen, T.E. Petersen, J. Gliemann, and L.K. Rasmussen Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide Biochem J 310 Pt 1 1995 91 94
85. P.H. Jensen, P. Hojrup, H. Hager, M.S. Nielsen, L. Jacobsen, and O.F. Olesen Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC Biochem J 323 Pt 2 1997 539 546
86. P.H. Jensen, M.S. Nielsen, R. Jakes, C.G. Dotti, and M. Goedert Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation J Biol Chem 273 1998 26292 26294
87. P.J. Jensen, B.J. Alter, and K.L. O'Malley Alpha-synuclein protects naive but not dbcAMP-treated dopaminergic cell types from 1-methyl-4-phenylpyridinium toxicity J Neurochem 86 2003 196 209
88. E. Jo, J. McLaurin, C.M. Yip, P. St George-Hyslop, and P.E. Fraser Alpha-synuclein membrane interactions and lipid specificity J Biol Chem 275 2000 34328 34334
89. E. Jo, N. Fuller, R.P. Rand, P. St George-Hyslop, and P.E. Fraser Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein J Mol Biol 315 2002 799 807
90. E. Junn, and M.M. Mouradian Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine Neurosci Lett 320 2002 146 150
91. E. Junn, R.D. Ronchetti, M.M. Quezado, S.Y. Kim, and M.M. Mouradian Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies Proc Natl Acad Sci U S A 100 2003 2047 2052
92. P.J. Kahle, M. Neumann, L. Ozmen, V. Muller, H. Jacobsen, and A. Schindzielorz Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain J Neurosci 20 2000 6365 6373
93. S.V. Kalivendi, S. Cunningham, S. Kotamraju, J. Joseph, C.J. Hillard, and B. Kalyanaraman Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide J Biol Chem 279 2004 15240 15247
94. S. Kanda, J.F. Bishop, M.A. Eglitis, Y. Yang, and M.M. Mouradian Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation Neuroscience 97 2000 279 284
95. N.G. Kholodilov, M. Neystat, T.F. Oo, S.E. Lo, K.E. Larsen, and D. Sulzer Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury J Neurochem 73 1999 2586 2599
96. T.D. Kim, S.R. Paik, C.H. Yang, and J. Kim Structural changes in alpha-synuclein affect its chaperone-like activity in vitro Protein Sci 9 2000 2489 2496
97. D. Kirik, C. Rosenblad, C. Burger, C. Lundberg, T.E. Johansen, and N. Muzyczka Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system J Neurosci 22 2002 2780 2791
98. D. Kirik, L.E. Annett, C. Burger, N. Muzyczka, R.J. Mandel, and A. Bjorklund Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease Proc Natl Acad Sci U S A 100 2003 2884 2889
99. T. Kitada, S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, and S. Minoshima Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism Nature 392 1998 605 608
100. H.L. Klawans, R.W. Stein, C.M. Tanner, and C.G. Goetz A pure parkinsonian syndrome following acute carbon monoxide intoxication Arch Neurol 39 1982 302 304
101. R.L. Klein, M.A. King, M.E. Hamby, and E.M. Meyer Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra Hum Gene Ther 13 2002 605 612
102. H. Kobayashi, R. Kruger, K. Markopoulou, Z. Wszolek, B. Chase, and H. Taka Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease Brain 126 2003 32 42
103. N.W. Kowall, P. Hantraye, E. Brouillet, M.F. Beal, A.C. McKee, and R.J. Ferrante MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons Neuroreport 11 2000 211 213
104. R. Kruger, W. Kuhn, T. Muller, D. Woitalla, M. Graeber, and S. Kosel Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease Nat Genet 18 1998 106 108
105. S. Kuzuhara, H. Mori, N. Izumiyama, M. Yoshimura, and Y. Ihara Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study Acta Neuropathol (Berl) 75 1988 345 353
106. M. Lakso, S. Vartiainen, A.M. Moilanen, J. Sirvio, J.H. Thomas, and R. Nass Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein J Neurochem 86 2003 165 172
107. J.W. Langston, P. Ballard, J.W. Tetrud, and I. Irwin Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 1983 979 980
108. H.A. Lashuel, B.M. Petre, J. Wall, M. Simon, R.J. Nowak, and T. Walz Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils J Mol Biol 322 2002 1089 1102
109. J.H. Lee, H.J. Shin, C.S. Chang, and S.R. Paik Comparisons of the NACP self-oligomerizations induced by Abeta25-35 in the presence of dicyclohexylcarbodiimide and N-(ethoxycarbonyl)-2-ethoxy-1,2-dihydroquinoline Neurochem Res 23 1998 1427 1434
110. F.J. Lee, F. Liu, Z.B. Pristupa, and H.B. Niznik Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis FASEB J 15 2001 916 926
111. H.J. Lee, C. Choi, and S.J. Lee Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form J Biol Chem 277 2002 671 678
112. H.J. Lee, S.Y. Shin, C. Choi, Y.H. Lee, and S.J. Lee Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors J Biol Chem 277 2002 5411 5417
113. H.J. Lee, F. Khoshaghideh, S. Patel, and S.J. Lee Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway J Neurosci 24 2004 1888 1896
114. V. Lehmensiek, E.M. Tan, J. Schwarz, and A. Storch Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro Neuroreport 13 2002 1279 1283
115. Y. Leng, T.N. Chase, and M.C. Bennett Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm J Biol Chem 276 2001 28212 28218
116. G. Lennox, J. Lowe, K. Morrell, M. Landon, and R.J. Mayer Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease J Neurol Neurosurg Psychiatry 52 1989 67 71
117. C.F. Lippa, H. Fujiwara, D.M. Mann, B. Giasson, M. Baba, and M.L. Schmidt Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes Am J Pathol 153 1998 1365 1370
118. C.F. Lippa, M.L. Schmidt, V.M. Lee, and J.Q. Trojanowski Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease Ann Neurol 45 1999 353 357
119. J. Lowe Lewy bodies D.B. Calne Neurodegenerative Diseases 1994 WB Saunders and Co. Philadelphia 51 69
120. J. Lowe, H. McDermott, M. Landon, R.J. Mayer, and K.D. Wilkinson Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases J Pathol 161 1990 153 160
121. J. Lowe, H. McDermott, I. Pike, I. Spendlove, M. Landon, and R.J. Mayer Alpha B crystallin expression in non-lenticular tissues and selective presence in ubiquitinated inclusion bodies in human disease J Pathol 166 1992 61 68
122. A.B. Manning-Bog, A.L. McCormack, M.G. Purisai, L.M. Bolin, and D.A. Di Monte Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration J Neurosci 23 2003 3095 3099
123. K. Markopoulou, Z.K. Wszolek, R.F. Pfeiffer, and B.A. Chase Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism Ann Neurol 46 1999 374 381
124. L. Maroteaux, and R.H. Scheller The rat brain synucleins; family of proteins transiently associated with neuronal membrane Brain Res Mol Brain Res 11 1991 335 343
125. L. Maroteaux, J.T. Campanelli, and R.H. Scheller Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal J Neurosci 8 1988 2804 2815
126. E. Masliah, A. Iwai, M. Mallory, K. Ueda, and T. Saitoh Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease Am J Pathol 148 1996 201 210
127. E. Masliah, E. Rockenstein, I. Veinbergs, M. Mallory, M. Hashimoto, and A. Takeda Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders Science 287 2000 1265 1269
128. P.J. McLean, H. Kawamata, S. Ribich, and B.T. Hyman Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations J Biol Chem 275 2000 8812 8816
129. P.J. McLean, H. Kawamata, and B.T. Hyman Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons Neuroscience 104 2001 901 912
130. K.S. McNaught, and P. Jenner Proteasomal function is impaired in substantia nigra in Parkinson's disease Neurosci Lett 297 2001 191 194
131. K.S. McNaught, R. Belizaire, O. Isacson, P. Jenner, and C.W. Olanow Altered proteasomal function in sporadic Parkinson's disease Exp Neurol 179 2003 38 46
132. E. Mezey, A. Dehejia, G. Harta, M.I. Papp, M.H. Polymeropoulos, and M.J. Brownstein Alpha synuclein in neurodegenerative disorders: murderer or accomplice? Nat Med 4 1998 755 757
133. E. Mezey, A.M. Dehejia, G. Harta, N. Tresser, S.F. Suchy, and R.L. Nussbaum Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease Mol Psychiatry 3 1998 493 499
134. Y. Mizuno, H. Yoshino, S. Ikebe, N. Hattori, T. Kobayashi, and S. Shimoda-Matsubayashi Mitochondrial dysfunction in Parkinson's disease Ann Neurol 44 1998 S99 S109
135. F. Mori, K. Tanji, M. Yoshimoto, H. Takahashi, and K. Wakabayashi Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment Exp Neurol 176 2002 98 104
136. E. Munoz, P. Pastor, M.J. Marti, R. Oliva, and E. Tolosa A new mutation in the parkin gene in a patient with atypical autosomal recessive juvenile parkinsonism Neurosci Lett 289 2000 66 68
137. S. Nakajo, K. Tsukada, K. Omata, Y. Nakamura, and K. Nakaya A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation Eur J Biochem 217 1993 1057 1063
138. Y. Nakazato, A. Sasaki, J. Hirato, and Y. Ishida Immunohistochemical localization of neurofilament protein in neuronal degenerations Acta Neuropathol (Berl) 64 1984 30 36
139. V. Narayanan, and S. Scarlata Membrane binding and self-association of alpha-synucleins Biochemistry 40 2001 9927 9934
140. L. Narhi, S.J. Wood, S. Steavenson, Y. Jiang, G.M. Wu, and D. Anafi Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation J Biol Chem 274 1999 9843 9846
141. M. Necula, C.N. Chirita, and J. Kuret Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro J Biol Chem 278 2003 46674 46680
142. Y. Oluwatosin-Chigbu, A. Robbins, C.W. Scott, J.L. Arriza, J.D. Reid, and J.R. Zysk Parkin suppresses wild-type alpha-synuclein-induced toxicity in SHSY-5Y cells Biochem Biophys Res Commun 309 2003 679 684
143. M. Orth, S.J. Tabrizi, A.H. Schapira, and J.M. Cooper Alpha-synuclein expression in HEK293 cells enhances the mitochondrial sensitivity to rotenone Neurosci Lett 351 2003 29 32
144. N. Ostrerova, L. Petrucelli, M. Farrer, N. Mehta, P. Choi, and J. Hardy Alpha-synuclein shares physical and functional homology with 14-3-3 proteins J Neurosci 19 1999 5782 5791
145. N. Ostrerova-Golts, L. Petrucelli, J. Hardy, J.M. Lee, M. Farer, and B. Wolozin The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity J Neurosci 20 2000 6048 6054
146. S.R. Paik, J.H. Lee, D.H. Kim, C.S. Chang, and Y.S. Kim Self-oligomerization of NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer's disease amyloid, observed in the presence of a C-terminal A beta fragment (residues 25-35) FEBS Lett 421 1998 73 76
147. S.R. Paik, H.J. Shin, J.H. Lee, C.S. Chang, and J. Kim Copper(II)-induced self-oligomerization of alpha-synuclein Biochem J 340 Pt 3 1999 821 828
148. S.R. Paik, H.J. Shin, and J.H. Lee Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide Arch Biochem Biophys 378 2000 269 277
149. B.A. Pappas, J.V. Gallivan, T. Dugas, M. Saari, and R. Ings Intraventricular 6-hydroxydopamine in the newborn rat and locomotor responses to drugs in infancy: no support for the dopamine depletion model of minimal brain dysfunction Psychopharmacology (Berl) 70 1980 41 46
150. M.A. Pappolla Lewy bodies of Parkinson's disease. Immune electron microscopic demonstration of neurofilament antigens in constituent filaments Arch Pathol Lab Med 110 1986 1160 1163
151. R.G. Perez, J.C. Waymire, E. Lin, J.J. Liu, F. Guo, and M.J. Zigmond A role for alpha-synuclein in the regulation of dopamine biosynthesis J Neurosci 22 2002 3090 3099
152. R.J. Perrin, W.S. Woods, D.F. Clayton, and J.M. George Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis J Biol Chem 275 2000 34393 34398
153. R.J. Perrin, W.S. Woods, D.F. Clayton, and J.M. George Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins J Biol Chem 276 2001 41958 41962
154. R.J. Perrin, J.E. Payton, D.H. Barnett, C.L. Wraight, W.S. Woods, and L. Ye Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines Neurosci Lett 349 2003 133 135
155. K. Petersen, O.F. Olesen, and J.D. Mikkelsen Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex Neuroscience 91 1999 651 659
156. L. Petrucelli, C. O'Farrell, P.J. Lockhart, M. Baptista, K. Kehoe, and L. Vink Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons Neuron 36 2002 1007 1019
157. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, and A. Dutra Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047
158. T. Powell Severe parkinsonism secondary to carbon monoxide poisoning J R
159. A.N. Pronin, A.J. Morris, A. Surguchov, and J.L. Benovic Synucleins are a novel class of substrates for G protein-coupled receptor kinases J Biol Chem 275 2000 26515 26522
160. S. Rathke-Hartlieb, P.J. Kahle, M. Neumann, L. Ozmen, S. Haid, and M. Okochi Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice J Neurochem 77 2001 1181 1184
161. Y. Ren, J. Zhao, and J. Feng Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation J Neurosci 23 2003 3316 3324
162. H.J. Rideout, K.E. Larsen, D. Sulzer, and L. Stefanis Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells J Neurochem 78 2001 899 908
163. D.C. Robertson, O. Schmidt, N. Ninkina, P.A. Jones, J. Sharkey, and V.L. Buchman Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice J Neurochem 89 2004 1126 1136
164. J.C. Rochet, K.A. Conway, and P.T. Lansbury Jr. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein Biochemistry 39 2000 10619 10626
165. Y. Saito, M. Kawai, K. Inoue, R. Sasaki, H. Arai, and E. Nanba Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course J Neurol Sci 177 2000 48 59
166. P. Sangchot, S. Sharma, B. Chetsawang, J. Porter, P. Govitrapong, and M. Ebadi Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture Dev Neurosci 24 2002 143 153
167. A.H. Schapira, M. Gu, J.W. Taanman, S.J. Tabrizi, T. Seaton, and M. Cleeter Mitochondria in the etiology and pathogenesis of Parkinson's disease Ann Neurol 44 1998 S89 S98
168. M.G. Schlossmacher, M.P. Frosch, W.P. Gai, M. Medina, N. Sharma, and L. Forno Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies Am J Pathol 160 2002 1655 1667
169. D. Seilhean, J. Takahashi, K.H. El Hachimi, H. Fujigasaki, A.S. Lebre, and V. Biancalana Amyotrophic lateral sclerosis with neuronal intranuclear protein inclusions Acta Neuropathol (Berl) 108 2004 81 87
170. J.H. Seo, J.C. Rah, S.H. Choi, J.K. Shin, K. Min, and H.S. Kim Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway FASEB J 16 2002 1826 1828
171. L.C. Serpell, J. Berriman, R. Jakes, M. Goedert, and R.A. Crowther Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation Proc Natl Acad Sci U S A 97 2000 4897 4902
172. N. Sharma, P.J. McLean, H. Kawamata, M.C. Irizarry, and B.T. Hyman Alpha-synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies Acta Neuropathol (Berl) 102 2001 329 334
173. R. Sharon, M.S. Goldberg, I. Bar-Josef, R.A. Betensky, J. Shen, and D.J. Selkoe Alpha-synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins Proc Natl Acad Sci U S A 98 2001 9110 9115
174. T.B. Sherer, R. Betarbet, A.K. Stout, S. Lund, M. Baptista, and A.V. Panov An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage J Neurosci 22 2002 7006 7015
175. H. Shimura, N. Hattori, S. Kubo, Y. Mizuno, S. Asakawa, and S. Minoshima Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase Nat Genet 25 2000 302 305
176. H. Shimura, M.G. Schlossmacher, N. Hattori, M.P. Frosch, A. Trockenbacher, and R. Schneider Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease Science 293 2001 263 269
177. A.B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, and J. Kachergus Alpha-synuclein locus triplication causes Parkinson's disease Science 302 2003 841 843
178. H. Snyder, K. Mensah, C. Theisler, J. Lee, A. Matouschek, and B. Wolozin Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function J Biol Chem 278 2003 11753 11759
179. D.D. Song, C.W. Shults, A. Sisk, E. Rockenstein, and E. Masliah Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP Exp Neurol 186 2004 158 172
180. J.M. Souza, B.I. Giasson, Q. Chen, V.M. Lee, and H. Ischiropoulos Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies J Biol Chem 275 2000 18344 18349
181. J.M. Souza, B.I. Giasson, V.M. Lee, and H. Ischiropoulos Chaperone-like activity of synucleins FEBS Lett 474 2000 116 119
182. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
183. M.G. Spillantini, R.A. Crowther, R. Jakes, M. Hasegawa, and M. Goedert Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies Proc Natl Acad Sci U S A 95 1998 6469 6473
184. L. Stefanis, K.E. Larsen, H.J. Rideout, D. Sulzer, and L.A. Greene Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death J Neurosci 21 2001 9549 9560
185. N. Stefanova, L. Klimaschewski, W. Poewe, G.K. Wenning, and M. Reindl Glial cell death induced by overexpression of alpha-synuclein J Neurosci Res 65 2001 432 438
186. J.Y. Sung, J. Kim, S.R. Paik, J.H. Park, Y.S. Ahn, and K.C. Chung Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein J Biol Chem 276 2001 27441 27448
187. S.J. Tabrizi, M. Orth, J.M. Wilkinson, J.W. Taanman, T.T. Warner, and J.M. Cooper Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity Hum Mol Genet 9 2000 2683 2689
188. Y. Tanaka, S. Engelender, S. Igarashi, R.K. Rao, T. Wanner, and R.E. Tanzi Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis Hum Mol Genet 10 2001 919 926
189. M. Tanaka, Y.M. Kim, G. Lee, E. Junn, T. Iwatsubo, and M.M. Mouradian Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective J Biol Chem 279 2004 4625 4631
190. M.J. Thiruchelvam, J.M. Powers, D.A. Cory-Slechta, and E.K. Richfield Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice Eur J Neurosci 19 2004 845 854
191. G.K. Tofaris, R. Layfield, and M.G. Spillantini Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome FEBS Lett 509 2001 22 26
192. P.H. Tu, J.E. Galvin, M. Baba, B. Giasson, T. Tomita, and S. Leight Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein Ann Neurol 44 1998 415 422
193. K. Ueda, H. Fukushima, E. Masliah, Y. Xia, A. Iwai, and M. Yoshimoto Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease Proc Natl Acad Sci U S A 90 1993 11282 11286
194. V.N. Uversky, H.J. Lee, J. Li, A.L. Fink, and S.J. Lee Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations J Biol Chem 276 2001 43495 43498
195. J. Vaughan, A. Durr, J. Tassin, B. Bereznai, T. Gasser, and V. Bonifati The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. European Consortium on Genetic Susceptibility in Parkinson's Disease Ann Neurol 44 1998 270 273
196. M. Vila, S. Vukosavic, V. Jackson-Lewis, M. Neystat, M. Jakowec, and S. Przedborski Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP J Neurochem 74 2000 721 729
197. M.J. Volles, and P.T. Lansbury Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism Biochemistry 41 2002 4595 4602
198. M.J. Volles, S.J. Lee, J.C. Rochet, M.D. Shtilerman, T.T. Ding, and J.C. Kessler Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease Biochemistry 40 2001 7812 7819
199. C.R. Von, S. Kugler, M. Bahr, M. Weller, J. Dichgans, and J.B. Schulz Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals J Neurochem 77 2001 263 273
200. K. Wakabayashi, K. Matsumoto, K. Takayama, M. Yoshimoto, and H. Takahashi NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease Neurosci Lett 239 1997 45 48
201. K. Wakabayashi, M. Yoshimoto, S. Tsuji, and H. Takahashi Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy Neurosci Lett 249 1998 180 182
202. K. Wakabayashi, M. Yoshimoto, T. Fukushima, R. Koide, Y. Horikawa, and T. Morita Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies Neuropathol Appl Neurobiol 25 1999 363 368
203. Y. Wang, C. Lu, and Z. Ye Alpha-synuclein immunoreactivity and ultrastructural study of glial cytoplasmic inclusions in multiple system atrophy Chin Med J (Engl) 115 2002 1491 1495
204. T. Wang, Z. Liang, S. Sun, X. Cao, H. Peng, and F. Cao A novel point mutation in parkin gene was identified in an early-onset case of Parkinson's disease Zhonghua Yi Xue Yi Chuan Xue Za Zhi 20 2003 111 113
205. J.L. Webb, B. Ravikumar, J. Atkins, J.N. Skepper, and D.C. Rubinsztein Alpha-synuclein is degraded by both autophagy and the proteasome J Biol Chem 278 2003 25009 25013
206. P.H. Weinreb, W. Zhen, A.W. Poon, K.A. Conway, and P.T. Lansbury Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded Biochemistry 35 1996 13709 13715
207. A.M. Weissman Regulating protein degradation by ubiquitination Immunology Today 18 1997 189 198
208. T. Wisniewski, M. Haltia, J. Ghiso, and B. Frangione Lewy bodies are immunoreactive with antibodies raised to gelsolin related amyloid-Finnish type Am J Pathol 138 1991 1077 1083
209. J. Xu, S.Y. Kao, F.J. Lee, W. Song, L.W. Jin, and B.A. Yankner Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease Nat Med 8 2002 600 606
210. Y. Xu, Z. Liu, Y. Wang, E. Tao, G. Chen, and B. Chen A new point mutation on exon 2 of parkin gene in Parkinson's disease Zhonghua Yi Xue Yi Chuan Xue Za Zhi 19 2002 409 411
211. T. Yamada, P.L. McGeer, and E.G. McGeer Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins Acta Neuropathol (Berl) 84 1992 100 104
212. G. Yamin, C.B. Glaser, V.N. Uversky, and A.L. Fink Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein J Biol Chem 278 2003 27630 27635
213. J.J. Zarranz, J. Alegre, J.C. Gomez-Esteban, E. Lezcano, R. Ros, and I. Ampuero The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia Ann Neurol 55 2004 164 173
214. W. Zhou, M.S. Hurlbert, J. Schaack, K.N. Prasad, and C.R. Freed Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells Brain Res 866 2000 33 43
215. W. Zhou, J. Schaack, W.M. Zawada, and C.R. Freed Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture Brain Res 926 2002 42 50
216. M.J. Zigmond, T.G. Hastings, and R.G. Perez Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat Disord 8 2002 389 393